Onemednet Corp

Onemednet Corp(ONMD)股票分析

$0.580

-0.005 (-0.87%)收盘时

Loading chart…
High
0.600
Open
0.598
VWAP
0.58
Vol
131.31K
Mkt Cap
Low
0.573
Amount
76.72K
EV/EBITDA, TTM
0.00

OneMedNet Corporation is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (RWD), through its OneMedNet iRWD solution. The Company provides solutions within the clinical image archives of healthcare providers. It de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with technology and in-house clinical expertise, the Company meets the rigorous RWD life science requirements. OneMedNet iRWD offers advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data are indexed at each network site using artificial intelligence (AI)/ machine learning (ML) technology. This includes EHR, radiology, cardiology, lab, path, and others. In addition to its customized data packages, it also offers regulatory-grade, pre-packaged imaging RWD sets.

AI analysis of Onemednet Corp (ONMD)

sell

Onemednet Corp is not a good buy right now due to its current price of 0.58, which is significantly down 52.46% year-to-date. The stock shows a low RSI of 35.949, indicating it is oversold, but the negative catalysts, including a 19.42% decline over the last 20 days, suggest continued weakness. Additionally, the company has a concerning net income loss of -2,172,000 USD in the most recent quarter, which raises significant risk for investors.

估值指标

The current forward P/E ratio for Onemednet Corp (ONMD) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
高估
0.00
低估
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
高估
0.00
低估
0.00

Alphio AI Price Scenarios for ONMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ONMD

$0.77

情景价格

B

Base

Base · 50%ONMD

$0.68

情景价格

B

Bear

Bear · 25%ONMD

$0.57

情景价格

Whales holding ONMD

D

Discovery Capital Management, LLC

+ HoldingONMD

-15.59%

3M Return

事件时间线

2026-07-28 (ET)

09:30:00

OneMedNet Signs Agreement to Supply $11.5M Healthcare Data

2026-07-01 (ET)

18:00:00

OneMedNet Files to Sell 11.68M Shares of Common Stock

2026-03-18 (ET)

09:00:00

OneMedNet Announces Strategic Collaboration with Navidence

2026-02-27 (ET)

09:00:00

OneMedNet Launches RWD Platform, Accelerates Subscription Growth

2026-02-26 (ET)

08:50:00

OneMedNet Partners with ViuHealth for Strategic Collaboration

资讯

ONMD FAQ — answered by Alphio AI

OneMedNet Corporation is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data (RWD), through its OneMedNet iRWD solution. The Company provides solutions within the clinical image archives of healthcare providers. It de-identifies, searches, and curates a data archive locally, bringing a wealth of internal and third-party research opportunities to providers. By leveraging this extensive federated provider network, together with technology and in-house clinical expertise, the Company meets the rigorous RWD life science requirements. OneMedNet iRWD offers advanced technology, clinical expert curation, and service. Medical imaging and associated clinical data are indexed at each network site using artificial intelligence (AI)/ machine learning (ML) technology. This includes EHR, radiology, cardiology, lab, path, and others. In addition to its customized data packages, it also offers regulatory-grade, pre-packaged imaging RWD sets. It operates in the Industrials sector (COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH industry).

Onemednet Corp is not a good buy right now due to its current price of 0.58, which is significantly down 52.46% year-to-date. The stock shows a low RSI of 35.949, indicating it is oversold, but the negative catalysts, including a 19.42% decline over the last 20 days, suggest continued weakness. Additionally, the company has a concerning net income loss of -2,172,000 USD in the most recent quarter, which raises significant risk for investors.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始